Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 3 |
2023 | 3 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway.
Discov Oncol. 2023 Jul 1;14(1):118. doi: 10.1007/s12672-023-00737-9.
Discov Oncol. 2023.
PMID: 37392305
Free PMC article.
Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in China.
Lin Z, Zha J, Yi S, Li Z, Ping L, He X, Fan L, Yu H, Zheng Z, Xu W, Chen F, Xie Y, Chen B, Zhang H, Wang L, Ding K, Li W, Yang H, Zhao W, Qiu L, Li Z, Song Y, Xu B.
Lin Z, et al.
Clin Transl Oncol. 2023 Jun;25(6):1821-1829. doi: 10.1007/s12094-023-03081-0. Epub 2023 Feb 19.
Clin Transl Oncol. 2023.
PMID: 36808598
Item in Clipboard
Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway.
Tang Y, Zhong M, Pan G, Tan J, Xie C, Jiang Y, Yao J, Shan W, Lin J, Huang J, Liu Y, Li Z, Xu B, Zha J.
Tang Y, et al.
Pharmaceuticals (Basel). 2022 Dec 22;16(1):15. doi: 10.3390/ph16010015.
Pharmaceuticals (Basel). 2022.
PMID: 36678513
Free PMC article.
Item in Clipboard
Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.
Pan G, Zhong M, Yao J, Tan J, Zheng H, Jiang Y, Tang Y, Zhou H, Qin D, Yu X, Liu L, Li Z, Lin Z, Jiang Y, Xu B, Zha J.
Pan G, et al.
J Cancer Res Clin Oncol. 2023 Aug;149(9):5513-5529. doi: 10.1007/s00432-022-04473-5. Epub 2022 Dec 6.
J Cancer Res Clin Oncol. 2023.
PMID: 36471019
Item in Clipboard
Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis.
Shan W, Wu G, Huang Y, Zeng H, Xia W, Lin Z, Xu B.
Shan W, et al.
Ann Hematol. 2022 Aug;101(8):1741-1753. doi: 10.1007/s00277-022-04876-x. Epub 2022 Jun 11.
Ann Hematol. 2022.
PMID: 35688904
Item in Clipboard
Cite
Cite